Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research note released on Tuesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target on the stock.

Lipocine Trading Down 3.7 %

LPCN stock opened at $4.72 on Tuesday. Lipocine has a 1-year low of $2.44 and a 1-year high of $11.79. The firm has a market cap of $25.24 million, a PE ratio of -6.21 and a beta of 1.24. The business’s 50-day moving average price is $5.13 and its two-hundred day moving average price is $5.40.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. On average, analysts forecast that Lipocine will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC boosted its position in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.